Insmed Inc 2024 SR
The report highlights Insmed's progress in 2024 across key areas including patient advocacy, innovation, and environmental stewardship. Significant milestones include reporting positive Phase 3 results for brensocatib and expanding the global workforce by nearly 40%. The company achieved limited assurance for its Scope 1 and 2 greenhouse gas emissions for the first time. Insmed also launched new employee resource groups and formalised its inclusion and culture roadmap.
Company: Insmed Inc
Sector: Health Care
Country: United States
Year: 2024
Type: SR
Pages: 65
Insmed Inc
Responsibility Report
The report highlights Insmed's progress in 2024 across key areas including patient advocacy, innovation, and environmental stewardship. Significant milestones include reporting positive Phase 3 results for brensocatib and expanding the global workforce by nearly 40%. The company achieved limited assurance for its Scope 1 and 2 greenhouse gas emissions for the first time. Insmed also launched new employee resource groups and formalised its inclusion and culture roadmap.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Jul 18, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Women on Board
Women in Management
Employees